Singapore to India: Ephedrine Import Trade Route

The Singapore to India Ephedrine corridor is one of India's established pharmaceutical import routes from Singapore, with 1 shipments documented worth a combined $150.2K USD. The route is dominated by SANOFI-AVENTIS SINGAPORE PTE LTD, which alone accounts for roughly 100% of all import value, reflecting the consolidated nature of Singapore's ephedrine export sector.

Across 1 active Singapore suppliers, the average shipment value stands at $150.2K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 70% of all shipments, consistent with ephedrine's non-urgent bulk-order profile.

Shipment activity peaks during July–September, with an average transit time of 20 days port-to-port. The route has recorded an annual growth rate of 24.8%, placing it at rank #8 among India's top ephedrine import origins globally.

On the Indian buyer side, key Indian importers include SANOFI INDIA LIMITED. SANOFI INDIA LIMITED is the single largest Indian importer with 1 shipments valued at $150.2K USD.

India's ephedrine imports from Singapore are driven primarily by a handful of large-scale Singapore manufacturers. SANOFI-AVENTIS SINGAPORE PTE LTD with 1 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 1 active exporters signals a competitive but concentrated market — Indian buyers benefit from Singapore supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — SANOFI-AVENTIS SINGAPORE PTE LTD — together account for 100% of total trade value on this route. The average shipment value of $150.2K USD reflects primarily bulk commercial orders from large pharmaceutical distributors.

On the buying side, SANOFI INDIA LIMITED is the largest importer with 1 shipments worth $150.2K USD — representing 100% of all ephedrine imports from Singapore on this route.